These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22105597)

  • 1. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?
    Barosi G; Tefferi A; Barbui T;
    Leukemia; 2012 May; 26(5):1148-9. PubMed ID: 22105597
    [No Abstract]   [Full Text] [Related]  

  • 2. [Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
    Penka M; Schwarz J; Campr V; Pospíšilová D; Křen L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulíček P; Jonášová A; Kissová J; Kořístek Z; Schützová M; Vonke I; Walterová L;
    Vnitr Lek; 2012 Feb; 58(2):163-8. PubMed ID: 22463098
    [No Abstract]   [Full Text] [Related]  

  • 3. Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
    Dasanu CA; Schwartz RA; Bauer F; Davis LK; Silver JS; Reale MA
    Leuk Res; 2011 May; 35(5):e41-3. PubMed ID: 21288571
    [No Abstract]   [Full Text] [Related]  

  • 4. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
    Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
    Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the Côte d'Or area, France, during 1980-99.
    Girodon F; Jooste V; Maynadie M; Favre B; Schaeffer C; Carli P
    J Intern Med; 2005 Jul; 258(1):90-1. PubMed ID: 15953137
    [No Abstract]   [Full Text] [Related]  

  • 6. [Unclassified chronic myeloproliferative disorder (Ph negative/bcr rearrangement negative CML) with late appearing Philadelphia like chromosome].
    Hamada K; Takahashi I; Saika T; Komatsu M; Yorimitsu S; Urata T; Sunami K
    Rinsho Ketsueki; 1996 Mar; 37(3):221-7. PubMed ID: 8727346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Philadelphia chromosome-negative chronic myeloproliferative disease.
    Thiele J
    Am J Clin Pathol; 2009 Aug; 132(2):261-80. PubMed ID: 19605821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.
    Harrison C
    Br J Haematol; 2005 May; 129(3):293-306. PubMed ID: 15842653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
    Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV
    Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136
    [No Abstract]   [Full Text] [Related]  

  • 10. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Odenike O
    Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boiocchi L; Vener C; Savi F; Bonoldi E; Moro A; Fracchiolla NS; Iurlo A; Deliliers GL; Coggi G; Bosari S; Gianelli U
    J Clin Pathol; 2011 Mar; 64(3):226-31. PubMed ID: 21217153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
    Cornfield D; Shah U; Cross N; Bennett C; Sun G
    J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
    [No Abstract]   [Full Text] [Related]  

  • 14. Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms.
    Dahlström J; Zhang X; Ghaderi M; Hultcrantz M; Björkholm M; Xu D
    Haematologica; 2015 Oct; 100(10):e402-5. PubMed ID: 26185173
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hematologic phenotype versus cytogenic phenotype in 124 chronic myeloproliferative syndromes (1979-1987)].
    Sánchez-Fayos MP; Outeiriño J; Benítez J; Calabuig T; Prieto E; Sánchez-Guilarte J; Bosch JM; Rodríguez C; Sánchez-Fayos J
    Sangre (Barc); 1988 Dec; 33(6):491-6. PubMed ID: 3247625
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of Philadelphia translocation-negative myeloproliferative neoplasms: its impact on data from clinical trials.
    Naresh KN
    J Clin Oncol; 2009 Nov; 27(31):e175-6; author reply e177-8. PubMed ID: 19704052
    [No Abstract]   [Full Text] [Related]  

  • 18. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
    Kralovics R; Skoda RC
    Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group.
    Schwarz J; Penka M; Indrák K; Pospísilová D; Pytlík R; Dulícek P; Doubek M; Kren L; Campr V;
    Leukemia; 2008 Nov; 22(11):2118-9. PubMed ID: 18418405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.